Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. carries a market capitalization of 12.04B, placing it among publicly traded companies globally. Its enterprise value stands at 17.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.04B |
| Enterprise Value | 17.56B |
Share Statistics
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. currently has 1.47B shares outstanding.
| Shares Outstanding | 1.47B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. trades at a trailing price-to-earnings ratio of 43.17. The price-to-sales ratio is 3.32, and the price-to-book ratio stands at 3.15.
| PE Ratio | 43.17 |
| PS Ratio | 3.32 |
| PB Ratio | 3.15 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | 89.00 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. trades at an EV/EBITDA multiple of 29.41 and an EV/FCF ratio of 61.75. The EV/Sales ratio of 3.34 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 29.41 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.34 |
| EV / EBITDA | 29.41 |
| EV / EBIT | 29.41 |
| EV / FCF | 61.75 |
Financial Position
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. maintains a current ratio of 2.29, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.33, indicating elevated leverage, while an interest coverage ratio of 5.88 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 2.29 |
| Quick Ratio | 0.74 |
| Debt / Equity | 25.33 |
| Debt / EBITDA | 5.18 |
| Interest Coverage | 5.88 |
Financial Efficiency
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. posts a return on equity of 7.31 and a return on invested capital of 3.19.
| Return on Equity (ROE) | 7.31 |
| Return on Assets (ROA) | 2.26 |
| Return on Invested Capital (ROIC) | 3.19 |
| Return on Capital Employed (ROCE) | 5.45 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.68 |
Taxes
Over the trailing twelve months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has paid 58.96M in income taxes, reflecting an effective tax rate of 13.33.
| Income Tax | 58.96M |
| Effective Tax Rate | 13.33 |
Stock Price Statistics
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s stock has declined approximately -18.28959% over the past 52 weeks. The 50-day moving average sits at 9.92, while the 200-day moving average is 11.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | -18.28959% |
| 50-Day Moving Average | 9.92 |
| 200-Day Moving Average | 11.36 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. generated 5.26B in revenue and converted that into 404.91M in net income, yielding earnings per share of 0.26. EBITDA reached 597.21M, while operating income came in at 597.21M.
| Revenue | 5.26B |
| Gross Profit | 1.65B |
| Operating Income | 597.21M |
| Pretax Income | 442.22M |
| Net Income | 404.91M |
| EBITDA | 597.21M |
| EBIT | 597.21M |
| Earnings Per Share (EPS) | 0.26 |
Balance Sheet
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. holds 3.06B in cash and equivalents against 3.09B in total debt, resulting in a net debt position of 153.62M. Total book value stands at 5.56B, with working capital of 5.36B providing operational flexibility.
| Cash & Cash Equivalents | 3.06B |
| Total Debt | 3.09B |
| Net Debt | 153.62M |
| Equity (Book Value) | 5.56B |
| Book Value Per Share | 3.79 |
| Working Capital | 5.36B |
Cash Flow
After subtracting -196.38M in capital expenditures, free cash flow totaled -196.38M - equivalent to -0.13 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -196.38M |
| Free Cash Flow | -196.38M |
| FCF Per Share | -0.13 |
Margins
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates with a gross margin of 31.29, reflecting its pricing power and cost economics. The operating margin of 11.35 and net profit margin of 7.70 provide insight into operational efficiency.
| Gross Margin | 31.29 |
| Operating Margin | 11.35 |
| Pretax Margin | 8.41 |
| Profit Margin | 7.70 |
| EBITDA Margin | 11.35 |
Dividends & Yields
The company's payout ratio of 31.11 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.08 |
| Dividend Yield | N/A |
| Payout Ratio | 31.11 |
| Shareholder Yield | 9.24 |
| FCF Yield | 1.12 |
Stock Splits
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s most recent stock split took place on June 13, 2016 with a 5:8 split ratio.
| Last Split Date | 6/13/2016 |
| Split Ratio | 5:8 |
Scores
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. posts an Altman Z-Score of 3.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.42 |